Arix Bioscience said Friday its three group businesses had launched three new clinical trials boosting the company's pipeline. Iterum Therapeutics initiated a phase 3 clinical trial of its urinary tract Infections treatment -- the first of three planned phase 3 pivotal trials. Top-line results are expected in second half of 2019 and NDA submission anticipated by the end of 2019, the company said. Harpoon Therapeutics treated the first patient with its prostate cancer treatment (HPN424) in its phase 1 clinical study of metastatic castration-resistant prostate cancer patients. Verona Pharma had initiated a phase 2 clinical trial to evaluate its lung treatment (Nebulized RPL554) as an add on to Dual Bronchodilator Therapy for COPD maintenance treatment. Top line data is expected in the first quarter 2019. 'We are pleased to note the initiation of new trials by Iterum Therapeutics, Harpoon Therapeutics and Verona Pharma,' said Joe Anderson, CEO of Arix Bioscience.
0.00 (0.00%)delayed 16:57PM